{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-026544","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2026-06-01T12:55:34+00:00","discovered_at":"2026-06-01T13:00:00.524467+00:00","generated_at":"2026-06-01T13:00:26.464320+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board","bullets":["Company will seek strategic acquisition partner for clinical-stage pharma/med-tech operations.","Stuart D. Porter, founder of Denham Capital (over $12B committed), joins board effective May 29, 2026.","Strategy targets power equipment/services for hyperscale AI data centers; NERC projects 224 GW demand increase.","LIXT expects to maintain Nasdaq listing under ticker LIXT during transformation."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026544","json":"https://secwatch.observer/filing/0001493152-26-026544.json","markdown":"https://secwatch.observer/filing/0001493152-26-026544.md","text":"https://secwatch.observer/filing/0001493152-26-026544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T13:00:26.464320+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8f181a2c8a","claim":"Stuart D. Porter was appointed as Director at LIXTE BIOTECHNOLOGY HOLDINGS, INC..","evidence_excerpt":"On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001193125-26-249692","ticker":"ELOX","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2026-06-01T11:00:19+00:00","headline":"Eloxx Pharma: 1-for-11 reverse stock split effective May 29; appoints two independent directors","event_type":"other_material","sec_items":["3.02","3.03","5.03","5.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-249692","json":"https://secwatch.observer/filing/0001193125-26-249692.json","markdown":"https://secwatch.observer/filing/0001193125-26-249692.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/d261568d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm","comparable_excerpt":"the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm"}},{"accession":"0001104659-26-068521","ticker":"FDXF","company_name":"FedEx Freight Holding Company, Inc.","filed_at":"2026-06-01T10:46:03+00:00","headline":"FedEx Freight completes spin-off from FedEx; $600M drawn, new board and executives appointed","event_type":"other_material","sec_items":["1.01","2.03","3.03","5.03","5.01","5.02","5.05","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068521","json":"https://secwatch.observer/filing/0001104659-26-068521.json","markdown":"https://secwatch.observer/filing/0001104659-26-068521.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2082247/000110465926068521/0001104659-26-068521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2082247/000110465926068521/tm2615735d2_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm","comparable_excerpt":"each of John A. Smith, R. Brad Martin, Jeffrey A. Davis, Donald E. Frieson, Stephen E. Gorman, Robert A. King, Cindy J. Miller, Amy J. Salcido, and Samantha M. Smith was appointed to the Board","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2082247/000110465926068521/0001104659-26-068521-index.htm"}},{"accession":"0001829126-26-005831","ticker":"FXAC","company_name":"FortuneX Acquisition Corp","filed_at":"2026-05-29T21:32:49+00:00","headline":"FortuneX Acquisition closes IPO of 8.625M units at $10/unit, raising $86.25M gross","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-005831","json":"https://secwatch.observer/filing/0001829126-26-005831.json","markdown":"https://secwatch.observer/filing/0001829126-26-005831.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2121703/000182912626005831/0001829126-26-005831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2121703/000182912626005831/fortunexacq_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm","comparable_excerpt":"Effective May 19, 2026, in connection with the effectiveness of the Company’s Registration Statement, Becky Fallon, Sean Michael Deegan, and Robert Labbe became members of the board of directors (the “Board”) of the Company.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2121703/000182912626005831/0001829126-26-005831-index.htm"}},{"accession":"0001213900-26-061493","ticker":"OHAC","company_name":"Oceanhawk Acquisition Corp.","filed_at":"2026-05-27T20:01:23+00:00","headline":"Oceanhawk Acquisition Corp. closes upsized $160M IPO of 16M units at $10/unit","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061493","json":"https://secwatch.observer/filing/0001213900-26-061493.json","markdown":"https://secwatch.observer/filing/0001213900-26-061493.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2090787/000121390026061493/0001213900-26-061493-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2090787/000121390026061493/ea0292099-8k_oceanhawk.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm","comparable_excerpt":"On May 20, 2026, in connection with the IPO, each of Joseph Durnford, Ernest Miller, Jon Ryan, Mike Maggard, Dan Collingridge-Padbury and Jonathan Nickell (collectively, the “ Directors ”) was appointed to the board of directors of the Company (the “ Board ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2090787/000121390026061493/0001213900-26-061493-index.htm"}},{"accession":"0001628280-26-038219","ticker":"LCLN","company_name":"Lincoln International, Inc.","filed_at":"2026-05-26T21:19:13+00:00","headline":"Lincoln International completes IPO of 24.2M shares at $20.00, raising $473.7M in gross proceeds","event_type":"other_material","sec_items":["1.01","3.02","3.03","5.03","5.02","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-038219","json":"https://secwatch.observer/filing/0001628280-26-038219.json","markdown":"https://secwatch.observer/filing/0001628280-26-038219.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1925283/000162828026038219/0001628280-26-038219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1925283/000162828026038219/lincolninternational-closi.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm","comparable_excerpt":"Effective May 19, 2026, Ms. M. Christie Smith and Mr. John W. Oleniczak were appointed to the board of directors of the Company.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1925283/000162828026038219/0001628280-26-038219-index.htm"}},{"accession":"0001628280-26-038821","ticker":"ENS","company_name":"EnerSys","filed_at":"2026-05-28T20:15:50+00:00","headline":"EnerSys realigns to three segments, names presidents for NIS, IMS, PPS","event_type":"other_material","sec_items":["5.02","7.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 7.01, 9.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-038821","json":"https://secwatch.observer/filing/0001628280-26-038821.json","markdown":"https://secwatch.observer/filing/0001628280-26-038821.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1289308/000162828026038821/0001628280-26-038821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1289308/000162828026038821/ens-20260528.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm","comparable_excerpt":"As a result of the Company's Segment Realignment there will be a change in executive titles as follows: • Keith D. Fisher – President, Network & Infrastructure Solutions • Chad C. Uplinger – President, Industrial Mobility Solutions • Mark E. Matthews – Chief Technology Officer and President, Precision Power Solutions","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1289308/000162828026038821/0001628280-26-038821-index.htm"}},{"accession":"0001171843-26-003809","ticker":"CRMT","company_name":"AMERICAS CARMART INC","filed_at":"2026-05-29T21:30:17+00:00","headline":"America's Car-Mart forms special committee for strategic alternatives; appoints new independent director","event_type":"other_material","sec_items":["1.01","5.02","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-003809","json":"https://secwatch.observer/filing/0001171843-26-003809.json","markdown":"https://secwatch.observer/filing/0001171843-26-003809.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/799850/000117184326003809/0001171843-26-003809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/799850/000117184326003809/f8k_052926.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm","comparable_excerpt":"On May 22, 2026, the Board increased the size of the Board from nine members to ten members and appointed Adam Paul as an independent director, effective immediately.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/799850/000117184326003809/0001171843-26-003809-index.htm"}},{"accession":"0001636282-26-000056","ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-05-29T20:45:58+00:00","headline":"Spyre Therapeutics stockholders approve amended ESPP; director Peter Harwin resigns","event_type":"other_material","sec_items":["5.02","5.07","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-26-000056","json":"https://secwatch.observer/filing/0001636282-26-000056.json","markdown":"https://secwatch.observer/filing/0001636282-26-000056.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000056/0001636282-26-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000056/syre-20260527.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm","comparable_excerpt":"In addition, effective as of May 27, 2026, Peter Harwin resigned from the Board.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000056/0001636282-26-000056-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}